Seán Haughey (Dublin Bay North, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

791. To ask the Minister for Health if his Department will expand the RSV vaccine roll-out to include all babies aged under six months by September 2024 in line with NIAC recommendations; and if he will make a statement on the matter. [29876/24]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

As you are aware, the Government recently provided approval for an infant Respiratory Syncytial Virus (RSV) Immunisation Pathfinder Programme which will run between September 2024 and February 2025.

All newborn infants born during the programme will be offered immunisation against RSV after birth on site in Irish maternity hospitals. This immunisation will protect newborn infants when they are most vulnerable to the complications of RSV during the winter period when infection rates are at their highest. The risk is highest in children less than six months of age.

As well as protecting newborn infants, this programme will help maintain health service capacity during this coming winter season. The programme is based on NIAC advice and is a temporary programme put in place as an interim measure pending the outcome of Health Technology Assessments on RSV immunisation currently being undertaken by the Health Information and Quality Authority (HIQA).

A HTA is a multidisciplinary research process that collects and summarises information about a health technology. The information can cover a range of fields, including clinical effectiveness and safety, cost-effectiveness and budget impact, organisational and social aspects, and ethical and legal issues. The information is collected and presented in a systematic, unbiased and transparent manner.

As well as protecting infants against serious illness, this pathfinder programme also offers the HSE an opportunity to establish working mechanisms and to evaluate the programme.

It is a strategic initiative designed to explore innovative approaches to improving health outcomes within a community or population. Such programmes often serve as pilots or models that, if successful, can be scaled up and replicated in other settings.

The outcome of the HTAs, and learnings from the pathfinder programme once complete, will inform the development of any longer-term programme and future decision making on this matter.